PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Sodium valproate (with childbearing potential) - Mental Health disorders

PAD Profile : Sodium valproate (with childbearing potential) - Mental Health disorders

Keywords :
valproate semisodium
Brand Names Include :
Depakote, Episenta, Epival CR, Belvo

Traffic Light Status

Status 1 of 1.

Status :
Amber
Formulations :
  • Not Specified
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
11 September 2024
Surrey Heartlands Medicines Safety Committee (MSC)

The Medicine Safety Committee has updated the "Safer Prescribing aide-memoire" for primary care which provides guidance on safe prescribing of sodium valproate (for women of child bearing age) in line with the Medicines and Healthcare products Regulatory Agency (MHRA) recomendations. 
It includes a summary of how to manage these patients within primary care, links to clinical resources and searches/ templates available on clinical systems  (EMIS Web and SystmOne)

14 August 2024
Surrey Heartlands Medicines Safety Committee (MSC)

The Medicines Safety Committee recommend the MHRA 'Guidance on contraceptive methods and frequency of pregnancy testing to reduce inadvertent exposures during pregnancy in a woman taking a medicine of teratogenic potential' which can be found in the link below.

aide-memoire_table-2024.pdf (publishing.service.gov.uk)

07 August 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee have agreed an updated AMBER shared care document for valproate for people of childbearing potential aged under 55 with:

Licensed uses:

  • Epilepsy
  • Treatment of mania in bipolar disorder
  • Continuation of treatment after a manic episode

Off label uses (refer to primary care responsibilities in shared care document for advice)

  • Mood stabiliser in mood disorders and primary psychotic disorders, under the direction of a consultant psychiatrist
  • Prevention of atypical antipsychotic-induced seizures
  • Management of compulsive and aggressive behaviour

Associated BNF Codes

04. Central Nervous System
04.02.03. Drugs used for mania and hypomania
04.08.01. Control of epilepsy
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More